Close Menu

Most people agree that biotech is the future, and that Big Pharma companies should take an interest if they want to continue to thrive. Sanofi-Aventis has already made inroads into biotech with a $20 billion takeover of Genzyme. And while the deal is a "bet on the future," Genzyme's short-term benefits for Sanofi may be more important, says Jonathan Rockoff on the Wall Street Journal's Health Blog.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.